The Delaware Supreme Court has agreed to hear an appeal by GSK and other drugmakers, including Pfizer, Sanofi, and Boehringer Ingelheim, to dismiss over 70,000 lawsuits. These lawsuits claim that the discontinued heartburn drug Zantac caused cancer. The appeal seeks to overturn a lower court's decision that allows plaintiffs to present expert testimony on the alleged cancer link. The court's decision to review the case has led to a rise in GSK's share prices.